Pfizer in technology licensing deal with Xoma

Share this article:

Drug developer Xoma announced that it has licensed technology to Pfizer that can be used to screen and make antibody products, the Associated Press reported.

Xoma said it will license the technology for an upfront payment of $30 million, along with future royalty and milestone payments.

Xoma also licenses the technology to companies including Merck, Centocor and Alexion Pharmaceuticals. Xoma receives royalties from Genentech for its macular degeneration drug Lucentis because that drug uses its bacterial cell expression technology.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...